PULMONARY EDEMA THERAPEUTICS MARKET ANALYSIS

Pulmonary Edema Therapeutics MarketSize and Trends

Global Pulmonary Edema Therapeutics Market – Dynamics

The increasing prevalence of heart failure, a major cause of pulmonary edema is expected to propel growth of the global pulmonary edema therapeutics market. For instance, according to the Centers for Disease Control and Prevention, in 2020, around 6.2 million adults in the U.S. had heart failure. Moreover, in 2018, heart failure was mentioned on 379,800 death certificates (13.4%) in the U.S.

Recent product launches and approvals is expected to boost global pulmonary edema therapeutics market growth. For instance, on May 5, 2020, Farxiga (dapagliflozin), an oral tablet developed by AstraZeneca, a global biopharmaceutical company, was approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with reduced ejection fraction. Heart failure is a severe condition, which leads to cardiogenic pulmonary edema. These factors are expected to support global pulmonary edema therapeutics market growth over the forecast period.